Form 4: uniQure Executive Executes Tax-Related Share Sale

Kylie O'Keefe, Chief Customer & Strategy Officer at uniQure N.V., sold 15,936 shares to cover tax obligations upon the vesting of restricted share units.

Summary

• Kylie O'Keefe, Chief Customer & Strategy Officer, sold 15,936 ordinary shares of uniQure N.V. (QURE).
• The transaction occurred on June 11, 2026, at a weighted average price of $27.06 per share.
• The sale was non-discretionary, executed solely to satisfy tax withholding requirements related to the vesting of restricted share units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a strategic shift.

Positives

• The transaction was a mandatory tax-withholding event rather than a discretionary divestment of equity.

Negatives

• The sale reduces the executive's direct beneficial ownership in the company.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The sale was not a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that mandatory 'sell-to-cover' transactions are standard industry practice for executives receiving equity-based compensation and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for biotech firms regarding executive tax obligations.
• The use of automatic sale instructions is consistent with Rule 10b5-1(c) compliance observed across the pharmaceutical sector.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and limited to tax obligations.

Next Steps

• None specified.

Key Dates

Keywords

uniQure, QURE, insider trading, Form 4, biotech, equity compensation